Short answer
Oncology Institute, Inc. (TOI) filed an 8-K current report with the SEC on February 23, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure). Kimberly Tzoumakas appointed to TOI Board via unanimous written consent, effective Feb 23, 2026, filling existing vacancy.
Oncology Institute, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Kimberly Tzoumakas appointed to TOI Board via unanimous written consent, effective Feb 23, 2026, filling existing vacancy
- Cleared Nasdaq independence requirements; no committee assignments yet
- Compensation: $75,000/year paid quarterly plus RSU grant (size/timing TBD)
- Term expires at next annual meeting; expected to be renominated on management's slate
- No related-party transactions or third-party arrangements tied to her appointment
Item 7.01 · Regulation FD Disclosure
- Reg FD disclosure filed, but substantive content resides in the referenced exhibit: no financial figures or operational data included in the item text itself
- Boilerplate liability disclaimer confirms disclosed information is not incorporated by reference into future filings unless explicitly stated
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Oncology Institute, Inc. 8-K filings
Get the next TOI 8-K as it lands
Follow TOI for push alerts, or ask the research agent what this filing means.